Related references
Note: Only part of the references are listed.Discovery and development of surotomycin for the treatment of Clostridium difficile
Victoria Knight-Connoni et al.
JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY (2016)
Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production
Caroline H. Chilton et al.
PLOS ONE (2016)
Streptokinase Treatment Reverses Biofilm-Associated Antibiotic Resistance in Staphylococcus aureus
Nis Pedersen Jorgensen et al.
MICROORGANISMS (2016)
Biofilm-specific antibiotic tolerance and resistance
I. Olsen
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
Burden of Clostridium difficile Infection in the United States
Fernanda C. Lessa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model
Grace S. Crowther et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Multistate Point- Prevalence Survey of Health Care- Associated Infections
Shelley S. Magill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Spore Formation and Toxin Production in Clostridium difficile Biofilms
Ekaterina G. Semenyuk et al.
PLOS ONE (2014)
Development and Validation of a Chemostat Gut Model To Study Both Planktonic and Biofilm Modes of Growth of Clostridium difficile and Human Microbiota
Grace S. Crowther et al.
PLOS ONE (2014)
Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials
Kathleen M. Mullane et al.
AMERICAN JOURNAL OF NEPHROLOGY (2013)
Both Fidaxomicin and Vancomycin Inhibit Outgrowth of Clostridium difficile Spores
Charlotte A. Allen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Resolution of Clostridium difficile-Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin
Oliver A. Cornely et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing
David W. Eyre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Fidaxomicin Inhibits Spore Production in Clostridium difficile
Farah Babakhani et al.
CLINICAL INFECTIOUS DISEASES (2012)
Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
Pamela Sears et al.
CLINICAL INFECTIOUS DISEASES (2012)
Daptomycin-Mediated Reorganization of Membrane Architecture Causes Mislocalization of Essential Cell Division Proteins
Joe Pogliano et al.
JOURNAL OF BACTERIOLOGY (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection
Milagros Gonzales et al.
BMC INFECTIOUS DISEASES (2010)
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Maja Rupnik et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Antimicrobial-associated risk factors for Clostridium difficile infection
Robert C. Owens et al.
CLINICAL INFECTIOUS DISEASES (2008)
Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin
JN Anderl et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Mechanisms of antibiotic resistance in bacterial biofilms
PS Stewart
INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY (2002)
Role of biofilms in antimicrobial resistance
RM Donlan
ASAIO JOURNAL (2000)
Share Paper
